Form 8-K - Current report:
SEC Accession No. 0000950170-24-105987
Filing Date
2024-09-12
Accepted
2024-09-12 16:49:42
Documents
11
Period of Report
2024-09-11
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K onct-20240911.htm   iXBRL 8-K 51214
  Complete submission text file 0000950170-24-105987.txt   193171

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT onct-20240911.xsd EX-101.SCH 45466
13 EXTRACTED XBRL INSTANCE DOCUMENT onct-20240911_htm.xml XML 4715
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

EIN.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 241295516
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)